(via TheNewswire)

April 30, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“ SciSparc ”), is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario) (the " OBCA "). Shareholders approved the continuance into the OBCA by special resolution at the Company's special meeting of shareholders held on April 10, 2026.

In connection with the continuance, the Company has replaced its notice of articles and articles with new articles of continuance and by-laws, respectively, under the OBCA, which can be accessed at the Company’s profile at www.sedarplus.com . The CUSIP / ISIN numbers for the Company's common shares and the stock symbol for the Company's common shares remain unchanged.

About Neurothera Labs Inc.

Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty IR Manager Neurothera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2026 TheNewswire - All rights reserved.